Insider Buys Additional US$100k In Immunic Stock [Yahoo! Finance]
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight [Yahoo! Finance]
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Immunic to Present at the November 21st Virtual Investor Summit Microcap Event